RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), PRIME (European Union), Priority Review (Australia), Accelerated assessment (European Union)

Structure/Sequence

Sequence Code 9535613

Sequence Code 10051604

Sequence Code 10051610

Clinical Trials associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

NCT07467707

/ RecruitingPhase 3

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

Start Date26 May 2026

Sponsor / Collaborator

Bavarian Nordic A/S

[+4]

NCT07003984

/ Active, not recruitingPhase 3

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to <12 years of age.

Start Date05 Jun 2025

Sponsor / Collaborator

Bavarian Nordic A/S

NCT06928753

/ RecruitingPhase 4IIT

Real-world Effectiveness, Safety, and Immunogenicity of Chikungunya Vaccination During an Epidemic Period: an Ambispective Study in Réunion Island and French Guiana.

In the context of the ongoing chikungunya epidemic in Réunion Island and the anticipated epidemic in French Guiana, the investigators propose an ambispective study to evaluate the real-world effectiveness, safety, and immunogenicity of the recommended vaccines, IXCHIQ® and VIMKUNYA®, as defined by the French National Authority for Health (HAS).

Start Date18 Apr 2025

Sponsor / Collaborator-

100 Clinical Results associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

100 Translational Medicine associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

100 Patents (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

116

Literatures (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

01 Jan 2027·Methods in molecular biology (Clifton, N.J.)

In Silico Drug Design of Chikungunya Antivirals: Using Consensus Methods for Virtual Screening

Article

Author: Battini, Leandro

Structure-based virtual screening is an attractive strategy in drug design. It enables the selection of potential binders to target biomolecules with known molecular structures, providing a rational framework for studying their mechanisms of action and guiding further optimization. However, accurately predicting the free energy of binding remains an extremely challenging task, and the available tools only provide approximate estimates. In this context, one strategy to improve the predictive power of virtual screening and increase the probability of identifying true binders is to employ multiple docking algorithms and combine their results using a consensus method. In this chapter, we will describe a step-by-step methodology to perform this task. We will conduct a virtual screening using AutoDock Vina, AutoDock4, and LeDock, and then combine their results employing the Exponential Consensus Ranking algorithm. Finally, we will discuss possible extensions of this strategy, such as incorporating Molecular Dynamics simulations as an additional filter in the virtual screening or integrating the novel Artificial Intelligence-based methodologies into the consensus framework.

01 Jan 2027·Methods in molecular biology (Clifton, N.J.)

Overview of Chikungunya Virus Epidemiology, Biology, and Pathogenesis

Review

Author: Filomatori, Claudia ; Castro, Eliana F

Chikungunya virus (CHIKV), an arthropod-borne alphavirus within the Togaviridae family, is transmitted primarily by Aedes aegypti and Aedes albopictus. The virus causes an acute febrile illness characterized by severe, often bilateral polyarthralgia, with potential progression to chronic musculoskeletal pain and rare systemic complications involving cardiovascular and neurological systems. CHIKV exhibits a spherical, enveloped virion (~70 nm) with T = 4 icosahedral symmetry, incorporating E1/E2 glycoprotein heterodimers that mediate receptor binding and membrane fusion. Its positive-sense RNA genome (~11.8 kb) encodes nonstructural proteins for replication and structural proteins for virion assembly. Replication occurs in cytoplasmic spherules, involving synthesis of genomic and subgenomic RNAs, followed by glycoprotein maturation and budding at the plasma membrane. Epidemiologically, CHIKV has expanded beyond Africa and Asia, with major outbreaks driven by adaptive mutations enhancing transmission via A. albopictus. Since introduction to the Americas in 2013, the global incidence remains high, with >180,000 confirmed cases reported in 2025. Preventive strategies rely on vector control and vaccination; VLP-based vaccines (e.g., Vimkunya) show promise, while live-attenuated formulations face safety concerns. No licensed antivirals exist; current management is supportive, though investigational therapies targeting viral replication and immune modulation are under development.

01 Sep 2026·Journal of Integrative Medicine-JIM

Chikungunya fever—What we know and have done in the face of a new global public health threat

Review

Author: Jia, Jia ; Zhou, Rong-Yi ; Yu, Xiao-Lu ; Zhang, Yi ; Xie, Xin-Yue

Chikungunya fever (CHIKF) is an emerging global health threat caused by the chikungunya virus (CHIKV), whose main symptoms include fever, rash and severe joint pain. The disease is characterized by acute febrile illness and chronic arthralgia, resulting in significant morbidity and economic burden, and posing a significant and growing global public health challenge. CHIKV has spread to over 119 countries, with recent outbreaks in the Americas and Asia. Two vaccines, VLA1553 (live-attenuated) and PXVX0317 (virus-like, particle-based), have been approved and have shown high immunogenicity, although their accessibility remains limited. Pathogenesis involves matrix remodeling-associated protein 8-mediated viral entry and immune dysregulation contributing to chronic arthritis. Traditional Chinese medicine approaches emphasize the removal of dampness and heat as well as the activation of collaterals, which have a potential adjunctive value in chronic phase management of CHIKF. Despite advances in vaccine development for CHIKF, challenges remain in terms of global coverage, research on chronic disease pathways and comprehensive treatment. Multidisciplinary collaboration will be needed to curb the public health impact of CHIKF in the future. Please cite this article as: Yu XL, Zhou RY, Xie XY, Zhang Y, Jia J. Chikungunya fever-What we know and have done in the face of a new global public health threat. J Integr Med. 2026; 24(5):634-644.

News (Medical) associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

21 Aug 2026

·www.biospace.com

Bavarian Nordic Reports Strong First Half 2026 Results

COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released its financial calendar for 2027. Financial highlights Revenue in the second quarter (Q2) increased by 23% to DKK 2,034 million. Travel Health revenue increased by 45% (56% when adjusting for discontinued partnerships) to DKK 1,022 million, primarily driven by continued strong RabAvert/Rabipur sales (DKK 649 million, +55%), as well as strong Encepur sales (DKK 268 million, +58%) and the continued launch of Vimkunya (DKK 37 million, +415%). Public Preparedness revenue increased by 6% to DKK 975 million driven by a stronger-than-expected contract base in 2026, while also reflecting the normal quarterly phasing of revenue from this business. EBITDA in the second quarter (Q2) was DKK 925 million, corresponding to an EBITDA margin of 45%. Gross margin reached 61% driven by an advantageous product mix and strong manufacturing performance. First half (H1) total revenue was DKK 3,092 million, an increase of 3%, reflecting the strong growth in Travel Health, offset by lower Public Preparedness revenue in line with expectations (no material impact from mpox outbreaks expected in 2026). EBITDA in the first half was DKK 1,090 million, corresponding to an EBITDA margin of 35%. Updated full-year guidance The Company has upgraded its full-year guidance for 2026 and now expects revenue of approximately DKK 5,700 million, corresponding to the upper end of the previous guidance range (DKK 5,500 – 5,700 million). The EBITDA margin is now expected to reach approximately 30% (previously approximately 28%). Share buy-back The planned share buy-back program of DKK 500 million was completed in July. The company will initiate another share buy-back program in 2026 of up to DKK 750 million, reflecting the strength of the Company’s balance sheet and cash generation while preserving the ability to pursue value-accretive acquisition opportunities. DKK million Q2 2026 Q2 2025 H1 2026 H1 2025 2026 Guidance Revenue 2,034 1,652 3,092 2,998 ~5,700 EBITDA margin 45% 33% 35% 32% ~30% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We delivered a strong first half of 2026, with record Travel Health revenue, continued robust profitability and solid execution across our manufacturing network. Demand for our rabies vaccines remained exceptionally strong across key markets, while our chikungunya vaccine continued to gain traction in Europe following multiple launches during the period. In Public Preparedness, additional government contracts for our mpox/smallpox vaccine strengthened our revenue base and enhanced visibility beyond 2026, while further regulatory progress broadened the potential use of the vaccine across wider populations. Based on our first-half performance, operational momentum and the business secured for the remainder of the year, we remain confident in delivering our upgraded financial guidance for 2026.” Business highlights for the second quarter Additional regulatory approvals were obtained for the Vimkunya chikungunya vaccine in Switzerland and Canada, and Bavarian Nordic’s partner, Eurofarma, submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for the vaccine. Vimkunya was launched in the Netherlands, Belgium and Switzerland, and is now available in the US and 14 European countries. Additional launches are planned for the second half of 2026. Regulatory advancements were also made for the mpox and smallpox vaccine as the European Commission in August approved the use of MVA-BN for children 2 to less than 12 years of age following a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency in June. The Public Preparedness business was strengthened as the US Government exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS ® smallpox vaccine. Furthermore, another contract valued over DKK 700 million with an undisclosed government was received for delivery in 2026 and 2027. Financial calendar 2027 The dates for the annual and quarterly reports and the annual general meeting in 2027 have been determined as follows: Annual Report 2026 March 11, 2027 Annual General Meeting April 13, 2027 1 First quarter report (Q1) May 14, 2027 Half-year report (H1) August 25, 2027 Nine-month report (Q3) November 10, 2027 1 Pursuant to Article 12 of the Articles of Association, shareholders who wish to submit a request for proposals for consideration at the annual general meeting must lodge this with the Company no later than Monday, March 1, 2027. Conference call and webcast The management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via . To join the Q&A session, please register in advance via . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel: +45 44 74 99 58 Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com , Tel: +45 71 79 67 33 Company Announcement no. 36 / 2026 Attachments Bavarian Nordic H1 2026 Report Bavarian Nordic Reports Strong First Half 2026 Results

Drug ApprovalVaccineFinancial StatementAccelerated Approval

15 Jul 2026

·www.biospace.com

Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that its partner, Eurofarma, has submitted a marketing authorization application to the Brazilian Health Regulatory Agency (Anvisa) for Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. The submission represents a key milestone in the partnership established between Bavarian Nordic and Eurofarma and marks an important step toward making the vaccine available in one of the countries most affected by chikungunya. Brazil accounts for a substantial proportion of reported chikungunya cases and related deaths globally, underscoring the continued need for effective preventive measures against the disease. Paul Chaplin, President & CEO of Bavarian Nordic , said: “The submission to Anvisa represents an important milestone in our strategy to expand access to our chikungunya vaccine beyond traditional travel markets and into regions where the disease poses a significant and recurring public health burden. Through our partnership with Eurofarma, we are combining global vaccine innovation with strong local expertise to support access for populations living at risk of chikungunya. We look forward to working closely with Eurofarma and Anvisa throughout the review process.” João Siffert, Vice President of Innovation at Eurofarma , said: “The introduction of the vaccine reinforces Eurofarma’s commitment to expanding public access to innovative healthcare products capable of addressing important public health challenges with efficacy and safety. Chikungunya continues to spread in Brazil and generates a significant impact on patients, not only during the acute infection but also through chronic effects, affecting both patients and healthcare systems. This vaccine uses a modern and widely validated technology, with a favorable safety pro the ability to induce a rapid immune response, contributing to strengthening disease prevention efforts.” About the partnership with Eurofarma In January 2026, Bavarian Nordic entered into an exclusive distribution agreement with Eurofarma covering Brazil. Under the agreement, Eurofarma is responsible for regulatory activities, commercialization, and distribution of the vaccine in the territory, while Bavarian Nordic remains the manufacturer and supplier of the product. Eurofarma also holds a right of first refusal for future opportunities in the broader Latin American region. About CHIKV VLP CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization to prevent disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as one week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, supporting its use across a broad population. The vaccine has already been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA), Swissmedic and Health Canada under the trade name VIMKUNYA ® . About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries 1 . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years 2 . In 2025, more than 500,000 cases of chikungunya and nearly 200 associated deaths were reported worldwide 3 . More than half of the reported cases and associated deaths were reported from Brazil 4 . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile 5 . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . About Eurofarma Founded in 1972, Eurofarma covers key pharmaceutical segments and is the leader in medical prescriptions in Brazil. A Brazilian multinational company operating in 24 countries, with full coverage across Latin America and retail leadership in the region, the company also maintains operations in the United States and Africa, with more than 13,000 employees and 10 manufacturing facilities. In 2025, Eurofarma produced 630 million units. That same year, the company invested over USD 137 million in innovation projects and achieved net revenue exceeding USD 2.24 billion. For more information: . Contact investors: Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel. +45 33 26 83 83 US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 1 World Health Organization (WHO). Chikungunya. 2 European Centre for Disease Prevention and Control. Chikungunya virus disease . . 3 World Health Organization (WHO). WHO Rapid Risk Assessment - Chikungunya virus disease, Global v.1 . . 4 Pan American Health Organization (PAHO). Chikungunya: analysis by country. 5 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic’s Chikungunya Vaccine Submitted for Regulatory Approval in Brazil

Drug ApprovalVaccine

02 Jul 2026

·www.biospace.com

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA ® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older. The single-dose vaccine is the first virus-like particle (VLP) vaccine approved in Canada for protection against the mosquito-borne chikungunya virus, expanding preventive options for travelers to endemic and outbreak regions. This marks the fifth regulatory approval of VIMKUNYA, which has also been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Swissmedic. Paul Chaplin, President and CEO of Bavarian Nordic , said: “Health Canada’s approval marks an important milestone in our efforts to expand access to our chikungunya vaccine globally. We are pleased to strengthen preventive options for Canadian travelers with a differentiated single-dose vaccine against a disease that can cause a significant and long-lasting burden.” About VIMKUNYA ® Chikungunya vaccine (recombinant, adsorbed) VIMKUNYA is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization to prevent disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as one week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, supporting its use across a broad population. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries i . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years ii . In 2025, more than 500,000 cases of chikungunya and nearly 200 associated deaths were reported worldwide iii . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile iv . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com , Tel. +45 33 26 83 83 US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com i World Health Organization (WHO). Chikungunya. ii European Centre for Disease Prevention and Control. Chikungunya virus disease . . iii World Health Organization (WHO). WHO Rapid Risk Assessment - Chikungunya virus disease, Global v.1 . . iv Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

Drug ApprovalVaccine

100 Deals associated with Chikungunya Vaccine, Recombinant (Bavarian Nordic)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chikungunya Fever	United States	Bavarian Nordic A/S	14 Feb 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACR2026	Phase 3	Chikungunya Fever	3,816	CHIKV VLP vaccine	cxbwioqoug(tgveuapfbv) = faxarhlcva nsuarcnlzw (wgcbgptnch ) View more	Positive	06 Nov 2026
				Placebo	hmdynnfbii(pytceoqxqe) = ndvzfyhuwl jhklbisrsz (rvtjtcdhqt )
ACR2026	Not Applicable	Chikungunya Fever	101,838	CHIKV VLP vaccine	geqyggrmjf(kkbideejmb) = qtyfrxeqcr appvgexycl (eycsqddwnp )	Positive	06 Nov 2026
ACR2025	Phase 2/3	Chikungunya Fever	3,141	CHIKV VLP vaccine	wcndkurnzp(lfuvsklftx) = bmqrbemlhv zsumzybthq (jakvvylsbs ) View more	Positive	24 Oct 2025
				Placebo	vesvdllysy(mmtngmhsyi) = xfaouqpyrk onlhbzlhfz (alxmrxetmr )
NCT03992872 (Pubmed \| Lancet Microbe)	Phase 2	Alphavirus Infections	60	Previous alphavirus vaccine recipients	dvhwtyirtq(uevitpqnka) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events ckacbgdjxm (gztgzswpzi )	Positive	01 Apr 2025
				Alphavirus vaccine-naive controls
NCT05349617 (FDA_CBER) Manual	Phase 3	Chikungunya Fever	-	VIMKUNYA	xdxbuwajkh(pjzvxnmgya) = nbgpvrwiou rtqwospkky (yhfwvhklka, 582.3 - 892.7) View more	Positive	14 Feb 2025
				Placebo	xdxbuwajkh(pjzvxnmgya) = yhqpnjsklp rtqwospkky (yhfwvhklka, 6.5 - 10.0) View more
NCT05072080 (FDA_CBER) Manual	Phase 3	Chikungunya Fever	-	VIMKUNYA	ofrdpiyjpj(epsylxxhmh) = rmhlyyoivc jcihnufvcm (bdetxzekrm, 1504.1 - 1695.6) View more	Positive	14 Feb 2025
				Placebo	ofrdpiyjpj(epsylxxhmh) = bucugnirft jcihnufvcm (bdetxzekrm, 7.0 - 8.8) View more
NCT05349617 (CTgov)	Phase 3	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	mnqvsqfkwt = azluavdfww rnousylyrs (wuopxnnskf, ajkinkowzz - nwyjlzfnxw) View more	-	13 Dec 2024
				Placebo (Group 2 - Placebo)	mnqvsqfkwt = opqglbsstx rnousylyrs (wuopxnnskf, zneakwammw - nwyecvyqii) View more
NCT05072080 (CTgov)	Phase 3	Chikungunya Fever	3,258	CHIKV VLP/adjuvant (Group 1)	fgamdjckrn = fdxptxfqzi flbfkpgilq (dqshvpukou, vhxruyaosu - qscpskggeb) View more	-	30 Aug 2024
				CHIKV VLP/adjuvant (Group 2)	fgamdjckrn = iketeqzjyd flbfkpgilq (dqshvpukou, gfsdatsmyx - sqsdlddahs) View more
NCT02562482 (phase 2, Pubmed \| Vaccine)	Phase 2	Chikungunya Fever focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	itdbyslzeh(rombkyrfev) = gvvghvrgxq iyolupordq (nekeqphobq )	Positive	01 Oct 2023
				CHIKV VLP vaccine seronegative recipients	itdbyslzeh(rombkyrfev) = ugbowwpfcz iyolupordq (nekeqphobq )
NCT05065983 (CHIKV VLP, CTgov)	Phase 2	Chikungunya Fever	25	CHIKV VLP, adjuvanted	suuzduhlqz = dhojnpfjum asljaieyjs (pzfhauzanr, rhxeubwdht - tgfswimtqw) View more	-	28 Feb 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis